These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8549323)

  • 1. Antichlamydial activities of newly developed fluoroquinolones and their potential future role in the treatment of chlamydial respiratory infections.
    Soejima R; Niki Y; Kishomoto T; Kimura M; Kubota Y
    Drugs; 1995; 49 Suppl 2():257-9. PubMed ID: 8549323
    [No Abstract]   [Full Text] [Related]  

  • 2. In vitro and in vivo activities of sitafloxacin against Chlamydia spp.
    Miyashita N; Niki Y; Matsushima T
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3270-2. PubMed ID: 11600398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo antichlamydial activities of newly developed quinolone antimicrobial agents.
    Kimura M; Kishimoto T; Niki Y; Soejima R
    Antimicrob Agents Chemother; 1993 Apr; 37(4):801-3. PubMed ID: 8494377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of quinolones in chlamydial infection.
    Oriel JD
    Rev Infect Dis; 1989; 11 Suppl 5():S1273-6. PubMed ID: 2672254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo antichlamydial activities of HSR-903, a new fluoroquinolone antibiotic.
    Niki Y; Miyashita N; Kubota Y; Nakajima M; Matsushima T
    Antimicrob Agents Chemother; 1997 Apr; 41(4):857-9. PubMed ID: 9087506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chlamydial infections and the quinolones.
    Ronald AR; Peeling RW
    Eur J Clin Microbiol Infect Dis; 1991 Apr; 10(4):351-4. PubMed ID: 1864296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sparfloxacin, a new generation fluoroquinolone against S. pneumoniae respiratory infections.
    Niki Y; Tamada S; Nakabayashi M; Soejima R
    Drugs; 1995; 49 Suppl 2():420-2. PubMed ID: 8549385
    [No Abstract]   [Full Text] [Related]  

  • 8. [Recent fluoroquinolones. Highly effective weapons for ambulatory therapy].
    Stahlmann R; Lode H
    MMW Fortschr Med; 1999 Nov; 141(47):35-6. PubMed ID: 10912165
    [No Abstract]   [Full Text] [Related]  

  • 9. Two new fluoroquinolones.
    Med Lett Drugs Ther; 1992 Jun; 34(872):58-60. PubMed ID: 1317502
    [No Abstract]   [Full Text] [Related]  

  • 10. An automated image-based method for rapid analysis of Chlamydia infection as a tool for screening antichlamydial agents.
    Osaka I; Hills JM; Kieweg SL; Shinogle HE; Moore DS; Hefty PS
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4184-8. PubMed ID: 22615279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative in-vitro activity of levofloxacin against Chlamydia spp.
    Donati M; Rumpianesi F; Marchetti F; Sambri V; Cevenini R
    J Antimicrob Chemother; 1998 Nov; 42(5):670-1. PubMed ID: 9848456
    [No Abstract]   [Full Text] [Related]  

  • 12. [Fluoroquinolones in the therapy of gonorrheal-chlamydial infection (a clinical and electron microscopic study)].
    Delektorskiĭ VV; Iashkova GN; Fedorov SM; Kisina VI; Dubenskiĭ VV; Sammak UT; Tishchenko EL; Lebedeva TV; Lupan IN; Navolotskaia TI
    Antibiot Khimioter; 1993 Dec; 38(12):44-9. PubMed ID: 8085910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The role of respiratory quinolone in treatment of respiratory tract infections: focusing on gatifloxacin].
    Kohno S; Watanabe A; Matsushima T
    Jpn J Antibiot; 2002 Jun; 55(3):247-58. PubMed ID: 12199109
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical assessment of tosufloxacin tosilate.
    Kohno S
    J Infect Chemother; 2002 Mar; 8(1):19-27. PubMed ID: 11957115
    [No Abstract]   [Full Text] [Related]  

  • 15. In-vitro activity of moxifloxacin and other fluoroquinolones against Chlamydia species.
    Miyashita N; Fukano H; Yoshida K; Niki Y; Matsushima T
    J Infect Chemother; 2002 Mar; 8(1):115-7. PubMed ID: 11957133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of quinolones against Chlamydia pneumoniae.
    Hammerschlag MR
    Drugs; 1999; 58 Suppl 2():78-81. PubMed ID: 10553711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of newer fluoroquinolones in lower respiratory tract infections.
    Lode H; Allewelt M
    J Antimicrob Chemother; 2002 May; 49(5):709-12. PubMed ID: 12003962
    [No Abstract]   [Full Text] [Related]  

  • 18. [A new generation of fluoroquinolones--new possibilities for the treatment of respiratory community-acquired infections].
    Iakovlev SV
    Antibiot Khimioter; 2001; 46(6):38-42. PubMed ID: 11573324
    [No Abstract]   [Full Text] [Related]  

  • 19. [Oral fluoroquinolones. Rational antibiosis as needed].
    MMW Fortschr Med; 1999 Sep; 141(35):58-9. PubMed ID: 10897964
    [No Abstract]   [Full Text] [Related]  

  • 20. Modified Fluoroquinolones as Antimicrobial Compounds Targeting
    Vu TH; Adhel E; Vielfort K; Ha Duong NT; Anquetin G; Jeannot K; Verbeke P; Hjalmar S; Gylfe Å; Serradji N
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743189
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.